Evidence mapPaperPMID 39543645Full record

ReviewDiabetology & metabolic syndrome2024

Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes: a meta-analysis of randomized controlled trials.

Basma Ehab Amer, Mahmoud Shaaban Abdelgalil, Abdullah Ashraf Hamad, Kerollos Abdelsayed, Ahmed Elaraby, Ahmed Mohamed Abozaid, Mohamed Abd-ElGawad

Abstract readReview
In one paragraph

Review in Diabetology & metabolic syndrome, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Metformin Beyond Glycemic Control: Cardiovascular Protection and Diabetes Prevention.Journal of cardiovascular development and disease · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. The Prediabetes Wake-Up Call: Time for Proactive Endocrine Care.Indian journal of endocrinology and metabolism
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Basma Ehab AmerFaculty of Medicine, Benha University, Benha, Egypt. basma.ehab15@gmail.com.ORCID http://orcid.org/0000-0001-7787-5508
Mahmoud Shaaban AbdelgalilFaculty of Medicine, Ain-shams University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-7325-0129
Abdullah Ashraf HamadFaculty of Medicine, Menoufia University, Menoufia, Egypt.ORCID http://orcid.org/0000-0002-3849-0995
Kerollos AbdelsayedClinical Research Department, Magdi Yacoub Foundation, Aswan Heart Center, Aswan, Egypt.ORCID http://orcid.org/0009-0001-2499-5570
Ahmed ElarabyFaculty of Medicine, Al-Azhar University, Cairo, Egypt.ORCID http://orcid.org/0000-0001-6963-7307
Ahmed Mohamed AbozaidFaculty of Medicine, Tanta University, Tanta, Egypt.ORCID http://orcid.org/0000-0002-8834-4179
Mohamed Abd-ElGawadFaculty of Medicine, Fayoum University, Fayoum, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe conducted this meta-analysis of randomized controlled trials (RCTs) to compare the efficacy of adding metformin to lifestyle interventions versus lifestyle interventions alone in individuals with prediabetes. MATERIALS AND

methodsWe searched four databases from inception until March 20, 2024. Our primary outcomes included the incidence of type 2 diabetes, hemoglobin A1c (HbA1c), and fasting plasma glucose (FPG). Secondary outcomes included blood pressure, plasma lipids, and weight measurements. Dichotomous outcomes were pooled as the risk ratio (RR) and its 95% confidence interval (CI), while continuous outcomes were pooled as the standardized mean difference (SMD) and its 95% CI in the random effect model. All statistical analyses were conducted using the "meta" package of RStudio software.

resultsWe included 12 RCTs, comprising 2720 patients. Adding metformin to lifestyle interventions significantly reduced HbA1c levels (SMD = -0.10, 95% CI [-0.19, -0.01], P = 0.03) and the incidence of type 2 diabetes (RR = 0.85, 95% CI [0.75, 0.97], P = 0.01). Interestingly, adding metformin to lifestyle interventions was comparable to lifestyle interventions alone in terms of FPG at both 3 and 6 months; however, it significantly reduced FPG at 12 months (SMD = -0.34, 95% CI [-0.59, -0.08], P = 0.01). There were no significant differences between the two groups in terms of all secondary outcomes.

conclusionsOur findings suggest that adding metformin to lifestyle interventions may improve glycemic control in individuals with prediabetes and reduce their risk of progression to diabetes, compared to lifestyle interventions alone. A longer duration of this combined approach may be required to observe the desired effects.

Indexed as

FPGHbA1cLifestyleMetforminPrediabetesType 2 diabetes

Identifiers

PMID39543645
PMCPMC11562588

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.